

The Healthcare Outlook: Macro Challenges and Biotech Innovations
81 snips Sep 18, 2025
Asad Haider, Head of the U.S. Healthcare Business Unit at Goldman Sachs Research, dives into healthcare's recent struggles due to AI shifts and policy uncertainties. Amit Sinha, Head of Life Sciences Investing at Goldman Sachs Asset Management, discusses why private capital is crucial for biotech and highlights groundbreaking advancements in areas like genetics and immunology. Both guests uncover innovative pockets within the industry, from oral obesity treatments to oncology strategies, painting a hopeful picture amid challenges.
AI Snips
Chapters
Transcript
Episode notes
Why Healthcare Has Lagged
- Healthcare has underperformed five straight years, driven by macro rotations and sector-specific headwinds.
- Valuations are cheap but uncertainty and earnings revisions keep generalists away.
Policy Uncertainty Is A Key Drag
- Policy overhangs from Washington and regulatory shifts have pressured healthcare multiples and investor appetite.
- Clarity on policy or a rotation away from AI would be needed to materially reopen the sector.
Vaccine Guidance Has Become Unstable
- Vaccine policy and personnel changes have created acute uncertainty for COVID and broader vaccine demand.
- Shifts in guidelines and state-level mandate removals could meaningfully reduce uptake this season.